Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Recursion, Roche and Genentech unveiled the latest product of their nearly four-year artificial intelligence drug discovery collaboration. GSK ’s Blenrep was approved by the FDA for treatment of ...

The live event in Nashville, Tenn., featured 60-plus leaders, and also honored several companies with awards for supply chain excellence.

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

As weight loss market rival Novo Nordisk drew headlines for starting a bidding war over a potential $9bn acquisition of ...

Q3 2025 Earnings Call Transcript October 29, 2025 NiSource Inc. misses on earnings expectations. Reported EPS is $0.19 EPS, ...

Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the ...

Cipla declined 2.05% to Rs 1,508.90, extending losses for the second straight session after the company announced a management reshuffle involving the replacement of its managing director and global ...

Euro US Dollar, US Dollar Japanese Yen, Nasdaq 100, Gold Spot US Dollar. Read 's Market Analysis on Investing.com ...

For the Magnificent 7 group, Q3 earnings are expected to be up 11.5% from the same period last year on 15.4% higher revenues, ...

In a week filled with high-stakes earnings reports, major tech companies are taking center stage, influencing market dynamics and investor sentiment. The latest results from industry giants like ...

Eli Lilly And Company ( ($LLY) ) has released its Q3 earnings. Here is a breakdown of the information Eli Lilly And Company presented to its ...